文献速递肺结节与肺癌

全身抗肿瘤治疗与药物敏感肿瘤患者恶性胸腔积液控制率的回顾性分析

Is Systemic Anticancer Therapy Associated With Higher Rates of Malignant Pleural Effusion Control in People With Pharmacologically Sensitive Tumors?: A Retrospective Analysis of Prospectively Collected Data.
PubMed 文献 · Chest · 2021-05-21

该研究基于2008至2017年前瞻性收集的观察性队列数据,回顾性分析280例肺癌、乳腺癌、卵巢癌及血液系统恶性肿瘤所致恶性胸腔积液患者。

要点

  • 药物敏感肿瘤患者积液消退率高于非敏感肿瘤,但该差异主要受血液系统恶性肿瘤构成影响。
  • 校正混杂因素后,全身抗肿瘤治疗与积液消退无独立关联。
  • 化学性胸膜固定术是积液消退最强预测因素(校正OR 6.2,95%CI 3.3-11.7)。

核心结论

  • 在这项观察性研究中,全身抗肿瘤治疗与药物敏感肿瘤患者的恶性胸腔积液消退无独立关联。
  • 目前数据下,有症状的恶性胸腔积液患者无论基础肿瘤类型或拟行治疗如何,均应接受早期确定性胸膜干预。

研究设计与样本

  • 研究为对2008年5月11日至2017年8月6日前瞻性收集的观察性队列数据进行的回顾性分析。
  • 纳入诊断为肺癌、乳腺癌、卵巢癌及血液系统恶性肿瘤所致恶性胸腔积液的患者,共280例。

主要发现

  • 药物敏感肿瘤患者积液消退率高于非敏感肿瘤(53/127 [41.7%] vs 42/153 [27.5%];P = .01),且多发生在接受全身抗肿瘤治疗后。
  • 血液系统恶性肿瘤在敏感组中占比过高,且全身抗肿瘤治疗使用率和积液消退率均高。
  • 校正该因素及其他混杂因素后,药物敏感性、全身抗肿瘤治疗与积液消退之间无关联(校正OR 1.4;95%CI 0.5-4.1)。
  • 积液消退最强预测因素为化学性胸膜固定术(校正OR 6.2;95%CI 3.3-11.7)。
  • 敏感肿瘤中,接受全身抗肿瘤治疗后未行化学性胸膜固定术而积液消退者为14/52(26.9%;95%CI 15.6%-41.1%),未接受者为5/22(22.7%;95%CI 8.2%-47.2%)。

关键数值与推荐

  • 积液消退定义为影像学消退且拔除引流管或导管并停止干预。
  • 药物敏感肿瘤包括高级别淋巴瘤、小细胞肺癌或靶突变阳性肺癌、激素受体阳性乳腺癌或卵巢癌。

临床怎么用

  • 有症状的恶性胸腔积液患者应尽早接受确定性胸膜干预,不应仅依赖全身抗肿瘤治疗控制积液。
  • 化学性胸膜固定术与积液消退独立相关,是重要的临床处理手段。

局限性

  • 本研究为回顾性分析,尽管数据前瞻性收集,仍存在混杂因素。
  • 血液系统恶性肿瘤在药物敏感组中占比过高,可能影响组间比较。
  • 研究结果为观察性关联,需随机对照试验进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Malignant pleural effusions (MPEs) often cause symptoms, and guidelines recommend early definitive intervention. However, observational data suggest that systemic anticancer treatment (SACT) may control MPE caused by certain pharmacologically sensitive tumors. RESEARCH QUESTION: Is SACT associated with higher rates of MPE resolution in people with pharmacologically sensitive tumors? STUDY DESIGN AND METHODS: This was a retrospective analysis of prospectively collected data from an observational cohort study of people diagnosed with MPE from lung, breast, ovarian, and hematologic malignancy between May 11, 2008, and August 6, 2017. MPE resolution (defined as radiologic resolution with removal of drain or catheter and cessation of interventions) was compared in pharmacologically sensitive (high-grade lymphoma, small cell or target-mutation-positive lung cancer, and hormone-receptor-positive breast or ovarian cancer) and nonsensitive (remainder of cohort) tumors, with and without SACT. Secondary outcomes included time to resolution, 3-month resolution rates, and total pleural interventions. RESULTS: Of 280 patients, 127 had sensitive and 153 had nonsensitive tumors. One hundred seventy-one received SACT, and 109 did not. More patients with sensitive tumors achieved MPE resolution than those with nonsensitive tumors (53/127 [41.7%] vs 42/153 [27.5%]; P = .01), and this occurred predominantly after receipt of SACT. However, hematologic malignancies were overrepresented in the sensitive group, with high rates of SACT use and MPE resolution. After adjustment for this and other confounders, no relationship was found among pharmacologic sensitivity, SACT, and MPE resolution (adjusted OR, 1.4; 95% CI, 0.5-4.1). The strongest predictor of MPE resolution was administration of chemical pleurodesis (adjusted OR, 6.2; 95% CI, 3.3-11.7). In sensitive tumors, MPE resolution occurred without chemical pleurodesis in 14 of 52 patients (26.9%; 95% CI, 15.6%-41.1%) after SACT and in 5 of 22 patients (22.7%; 95% CI, 8.2%-47.2%) without SACT. INTERPRETATION: In this observational study, SACT was not associated independently on MPE resolution in pharmacologically sensitive tumors. Randomized trials are required, but with current data, patients with symptomatic MPE should receive early definitive pleural intervention regardless of underlying tumor or intended treatment.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Holling N, Patole S, Medford ARL, et al. Is Systemic Anticancer Therapy Associated With Higher Rates of Malignant Pleural Effusion Control in People With Pharmacologically Sensitive Tumors?: A Retrospective Analysis of Prospectively Collected Data. Chest. 2021. PMID: 34023321. doi:10.1016/j.chest.2021.05.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。